MIBG With Dinutuximab



Status:Recruiting
Conditions:Brain Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:1 - 30
Updated:9/12/2018
Start Date:September 5, 2018
End Date:March 2022
Contact:Araz Marachelian, MD, MS
Email:amarachelian@chla.usc.edu
Phone:323-361-5687

Use our guide to learn which trials are right for you!

A Phase I Study of 131I-MIBG With Dinutuximab for Relapsed/Refractory Neuroblastoma

131I-Metaiodobenzylguanidine (131I-MIBG) is one of the most effective therapies utilized for
neuroblastoma patients with refractory or relapsed disease. In this pediatric phase 1 trial,
131I-MIBG will be given in combination with dinutuximab, a chimeric 14.18 monoclonal
antibody. This study will utilize a traditional Phase I dose escalation 3+3 design to
determine a recommended phase 2 pediatric dose. An expansion cohort of an additional 6
patients may then be enrolled.

131I-Metaiodobenzylguanidine (131I-MIBG) is one of the most effective therapies utilized for
neuroblastoma patients with refractory or relapsed disease. Data from pre-clinical and adult
studies suggest that radiation can enhance the efficacy of immunotherapy and targeted
therapies such as dinutuximab. This first pediatric phase 1 trial of 131I-MIBG in combination
with dinutuximab aims to determine the recommended phase 2 pediatric dose of these two
therapies in combination.

Inclusion Criteria:

- Patients must have a diagnosis of neuroblastoma either by histologic verification of
neuroblastoma and/or demonstration of tumor cells in the bone marrow with increased
urinary catecholamines

- Patients must have high risk neuroblastoma according to COG risk classification at the
time of study registration. Patients who were initially considered low or intermediate
risk, but then reclassified as high risk are also eligible.

- Patients must have at least ONE of the following: 1) Recurrent/progressive disease at
any time prior to study enrollment, 2) Refractory disease, 3) Persistent disease

- Patients must have at least ONE of the following: 1) Bone disease, 2) Any amount of
neuroblastoma tumor cells in the bone marrow, 3) At least one soft tissue lesion that
meets criteria for a TARGET lesion, 4) At least one non-target soft tissue lesion that
is not measurable, but had a biopsy positive for neuroblastoma and/or
ganglioneuroblastoma at any time prior to enrollment or is MIBG avid

- Patients must have a Lansky (≤16 years) or Karnofsky (> 16 years) score of at least 50

- Patients must have fully recovered from the acute toxic effects of all prior
chemotherapy, immunotherapy, or radiotherapy prior to entering this study.

- Patients must not have received any of the specified therapies as stated in the
protocol in the time period prior to registration

- Patients must not be receiving any other anti-cancer agents or radiotherapy at the
time of study entry or while on study.

- Patients must not be receiving other investigational medications (covered under
another IND) within 30 days of study entry or while on study.

- Patients must not be receiving chronic systemic corticosteroids at doses greater than
physiologic dosing (inhaled corticosteroids acceptable).

- Patient must meet the organ function and system function requirements as stated in the
protocol

Exclusion Criteria:

- Pregnancy, breast feeding, or unwillingness to use effective contraception during the
study.

- Patients who, in the opinion of the investigator, may not be able to comply with the
safety monitoring requirements of the study.

- Patients with disease of any major organ system that would compromise their ability to
withstand therapy.

- Patients who have received prior allogeneic stem cell transplant

- Patients who are on hemodialysis.

- Patients with an active or uncontrolled infection.

- Known history of human immunodeficiency virus (HIV) infection, hepatitis B, or
hepatitis C.

- Patients and/or families who are physically and psychologically unable to cooperate
with the radiation safety isolation.

- Patients with a history of having to discontinue anti-GD2 antibody therapy due to
toxicity are not eligible.

- Prior anti-GD2 therapy is not otherwise an exclusionary criteria unless it was given
in combination with therapeutic 131I-MIBG.

- Patient declines participation in NANT 2004-05, the NANT Biology Study
We found this trial at
12
sites
1405 Clifton Road Northeast
Atlanta, Georgia 30322
(404) 785-6000
Phone: 404-785-0853
AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus...
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Ann Arbor, MI 48109Bus: -
Ann Arbor, Michigan 48109
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
5721 S. Maryland Avenue
Chicago, Illinois 60637
Phone: 773-843-3943
?
mi
from
Chicago, IL
Click here to add this to my saved trials
3333 Burnet Avenue # Mlc3008
Cincinnati, Ohio 45229
 1-513-636-4200 
Phone: 513-636-9863
Cincinnati Children's Hospital Medical Center Patients and families from across the region and around the...
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
4650 Sunset Blvd
Los Angeles, California 90027
 (323) 660-2450
Phone: 323-361-5687
Childrens Hospital Los Angeles Children's Hospital Los Angeles is a 501(c)(3) nonprofit hospital for pediatric...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
South 34th Street
Philadelphia, Pennsylvania 19104
 215-590-1000
Phone: 215-590-0965
Children's Hospital of Philadelphia Since its start in 1855 as the nation's first hospital devoted...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
1600 Divisadero Street
San Francisco, California 94115
888.689.8273
Phone: 415-476-3831
UCSF Helen Diller Family Comprehensive Cancer Center UCSF’s long tradition of excellence in cancer research...
?
mi
from
San Francisco, CA
Click here to add this to my saved trials
Aurora, Colorado 80045
Phone: 720-777-8856
?
mi
from
Aurora, CO
Click here to add this to my saved trials
Boston, Massachusetts 02115
Phone: 617-632-4901
?
mi
from
Boston, MA
Click here to add this to my saved trials
Chapel Hill, North Carolina 27599
(919) 962-2211
Univ of North Carolina Carolina’s vibrant people and programs attest to the University’s long-standing place...
?
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Fort Worth, Texas 76104
Phone: 682-885-4007
?
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Seattle, Washington 98105
Phone: 206-987-5783
?
mi
from
Seattle, WA
Click here to add this to my saved trials